Flunarizine Hydrochloride

Phase 2Small molecule

SShanghai University of Traditional Chinese Medicine

Flunarizine Hydrochloride is one of 77 small molecule programs targeting Migraine Without Aura. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Migraine Without AuraActive, not recruiting

MigraineActive, not recruiting

EpilepsyActive, not recruiting

Migraine Without AuraPhase 1

Active, not recruiting

MigrainePreclinical

Active, not recruiting

EpilepsyPhase 2

Active, not recruiting

Competition

Competitive Landscape

357 competitors in Migraine

#DrugCompanyPhaseTrials

Emgality

Eli Lilly

Preclinical

19 2

Vyepti

Lundbeck

Preclinical

12 3

Savella

AbbVie

Preclinical

2 4

Botox

RRevance Therapeutics, Inc.

Preclinical

9 5

Flunarizine Hydrochloride

SShanghai University of Traditional Chinese Medicine

Phase 2

1 6

Viagra

VViatris Specialty LLC

Preclinical

2 7

Lidocain

Bayer

Preclinical

1 8

Bupivacaine Only

Pacira Pharmaceuticals, Inc

Preclinical

1 9

Non-Steroidal Anti-Inflammatory Drugs (NSAID)

Roche

Preclinical

1 10

Substance P

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Not yet recruiting

Migraine Without Aura

NCT07068815

Clinical

Trials by Indication[1]

Migraine Without Aura1 trial

Efficacy and Mechanism of Fu's Subcutaneous Needling Treatment for Migraine Without Aura

Not yet recruiting·GGuangzhou University of Chinese Medicine·Phase 1·NCT07068815·60 enrolled

Migraine1 trial

Study of Key Electro-acupuncture Technique on Migraine

Completed·SShanghai University of Traditional Chinese Medicine·N/A·NCT02580968·2 enrolled

Epilepsy1 trial

Flunarizine for Treatment Resistant Absence Epilepsy

Terminated·UUniversity of British Columbia·Phase 2·NCT06153186·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Flunarizine Hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Flunarizine Hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Flunarizine Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai University of Traditional Chinese Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShanghai University of Traditional Chinese Medicine

Flunarizine Hydrochloride

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Migraine Without Aura1 trial

Migraine1 trial

Epilepsy1 trial

References

Drug Info

Quick Facts

Related News